MDT Price Prediction Next Week
Based on the provided data and current market conditions, here's the analysis for MDT's price movement in the next trading week:
Technical Analysis
The technical indicators show:
- RSI at 71.89 indicates overbought conditions
- MACD at 1.63 suggests positive momentum
- Price is currently trading above both 20-day SMA (83.55) and 60-day SMA (85.05)
- Fibonacci resistance levels: R1 at 89.50, R2 at 91.93, R3 at 95.86
- Fibonacci support levels: S1 at 81.64, S2 at 79.21, S3 at 75.28
News Sentiment & Fundamental Factors
- MDT has shown strong momentum, gaining 9.38% over the past month
- The company will release earnings on February 18, 2025, with projected EPS of $1.36 (4.62% YoY increase) and revenue of $8.33 billion (2.95% YoY growth)
- Recent AI-powered clinical study success in atrial fibrillation detection shows promising technological advancement
- The stock is showing signs of a "bearish-to-bullish" reversal pattern after recovering from its $69 low in late 2023
Price Target for Next Week Based on technical and fundamental analysis:
- Resistance: $91.93 (Fibonacci R2)
- Support: $88.82 (Current week's projected low)
- Most likely trading range: $88.64 - $91.74
Trading Recommendation BUY with the following parameters:
- Entry point: Current market price ($90.19)
- Stop loss: $88.64 (projected support)
- Target: $91.74 (near Fibonacci R2)
- Risk/Reward ratio: Approximately 2.3:1
The stock shows strong momentum and positive technical signals, supported by upcoming earnings catalyst and AI developments. However, traders should be cautious of the overbought RSI reading, which might lead to short-term consolidation before further upside.
MDT Similar Chart Price Prediction
The price of MDT is predicted to go up -5.5%, based on the high correlation periods with CNTX. The similarity of these two price pattern on the periods is 97.89%.
MDT
CNTX
Down: -5.5%Similarity: 97.89%
MDT Revenue Forecast
MDT EPS Forecast
MDT FAQs
What is revenue forecast for next quarter？
What is eps forecast for next quarter？
MDT VS S&P500
Medtronic has historically held roughly 50% share in its core heart devices. It's also the market leader in spinal products, insulin pumps, and neuromodulators for chronic pain.
Medtronic's pipeline contains treatments for atrial fibrillation, mitral valve disease, and renal denervation for hypertension. If these new therapies prove effective, Medtronic could dominate three more potentially large markets.
Medtronic often finds novel ways to apply familiar technologies, like using the implantable electronic stimulation in pacemakers to address fecal incontinence and chronic pain.
MDT Analyst's Forecast
Matt Miksic
Barclays
Buy
Price Target
$105 → $109
Upside
+27.22%
Barclays analyst Matt Miksic raised the firm's price target on Medtronic to $109 from $105 and keeps an Overweight rating on the shares. The firm continues to expect accelerating earnings growth in the second half of 2025, driven by solid mid-single-digit sales growth and unwinding multi-year currency hedge expenses. It continues to view the selloff post Medtronic's fiscal Q2 results as unwarranted and remain bullish into the second half of the fiscal year.
Lee Hambright
Bernstein
Buy
Price Target
$96 → $97
Upside
+15.33%
Larry Biegelsen
Wells Fargo
Buy
Price Target
$106 → $98
Upside
+16.51%